Empagliflozin CV Outcomes Data: Is Sum Of The Parts Greater Than Whole?
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer and Lilly focus on CV death, are not seeking broader indication for Jardiance based on less impressive primary composite endpoint results.
You may also be interested in...
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.
Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.